Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 8,796 Shares

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 8,796 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, August 24th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $82.53, for a total transaction of $24,759.00.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Trading Up 0.3%

Shares of IRON stock traded up $0.26 on Wednesday, reaching $82.67. 586,890 shares of the company’s stock were exchanged, compared to its average volume of 329,310. The company’s fifty day simple moving average is $76.56 and its 200 day simple moving average is $69.95. The stock has a market capitalization of $316.63 million, a PE ratio of -12.56 and a beta of 1.00. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of large investors have recently made changes to their positions in IRON. State of Wyoming purchased a new stake in Disc Medicine in the 2nd quarter worth approximately $25,000. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine in the 4th quarter valued at $33,000. Allworth Financial LP purchased a new position in Disc Medicine in the 2nd quarter valued at $46,000. Nykredit A S acquired a new stake in Disc Medicine during the 2nd quarter worth $103,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Disc Medicine during the 4th quarter worth $141,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IRON has been the topic of a number of research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 target price on shares of Disc Medicine in a research report on Monday, August 17th. HC Wainwright lifted their price objective on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush restated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $106.50.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.